Results 221 to 230 of about 27,755 (279)
Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. [PDF]
Diabetes Obes MetabTsakiridis EE, Steinberg GR.
europepmc +1 more source
Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report. [PDF]
J Clin Med ResSato M +6 more
europepmc +1 more source
Pathogenesis of nonfamilial somatotroph adenomas.
J Clin Endocrinol MetabBen-Shlomo A, Melmed S.
europepmc +1 more source
Calcium-Sensing Receptor Regulation of Gastrointestinal Hormone Secretion.
Endocr RevAnjom-Shoae J +4 more
europepmc +1 more source
GIP(3-30)NH2 – a tool for the study of GIP physiology
Current Opinion in Pharmacology, 2020 Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone impacting glucose, lipid and bone metabolism through the GIP receptor (GIPR). The GIP system has key species differences complicating the translation of findings from rodent to human physiology.
Mads Bank Lynggaard +3 more
openaire +4 more sources
GIP’s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3–30)NH2
Bone, 2020 Infusion of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) suppresses the bone resorption marker carboxy-terminal type 1 collagen crosslinks (CTX). Using separate and combined infusions of the selective GIP receptor (GIPR) antagonist, GIP(3-30)NH2, and GIP, we investigated how GIPR inhibition affects bone turnover markers.
Lærke S. Gasbjerg +8 more
openaire +5 more sources